[
  {
    "ts": "2026-02-13T00:22:55+00:00",
    "headline": "West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook",
    "summary": "In the past week, West Pharmaceutical Services reported its 2025 results, with full-year sales rising to US$3.07 billion and net income edging up to US$493.7 million, while also issuing 2026 guidance that calls for first-quarter net sales of US$770 million to US$790 million and full-year net sales of US$3.22 billion to US$3.28 billion, including a foreign-exchange benefit. An important detail in that outlook is that organic net sales growth is expected to outpace reported growth,...",
    "url": "https://finance.yahoo.com/news/west-pharmaceutical-services-wst-5-002255335.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "55246e5f-e7bb-3c35-b982-e71b3a41a1fd",
      "content": {
        "id": "55246e5f-e7bb-3c35-b982-e71b3a41a1fd",
        "contentType": "STORY",
        "title": "West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook",
        "description": "",
        "summary": "In the past week, West Pharmaceutical Services reported its 2025 results, with full-year sales rising to US$3.07 billion and net income edging up to US$493.7 million, while also issuing 2026 guidance that calls for first-quarter net sales of US$770 million to US$790 million and full-year net sales of US$3.22 billion to US$3.28 billion, including a foreign-exchange benefit. An important detail in that outlook is that organic net sales growth is expected to outpace reported growth,...",
        "pubDate": "2026-02-13T00:22:55Z",
        "displayTime": "2026-02-13T00:22:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/06bbda48bd77be658a8c5765fd6bc2ab",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4G9ppBeYPHN150Vf7ljszA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/06bbda48bd77be658a8c5765fd6bc2ab.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rJ2VkF_7pHDs8.rNQqRscw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/06bbda48bd77be658a8c5765fd6bc2ab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/west-pharmaceutical-services-wst-5-002255335.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/west-pharmaceutical-services-wst-5-002255335.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "WST"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T13:00:36+00:00",
    "headline": "Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent",
    "summary": "Investing.com -- Merck (NYSE: MRK) stock rose 2% Friday morning after Deutsche Bank analyst James Shin upgraded the pharmaceutical giant from Hold to Buy, setting a price target of $150.00, up from $115.00.",
    "url": "https://finance.yahoo.com/news/merck-stock-upside-why-deutsche-130036976.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "29c16f99-eae1-36a9-bb00-b03a1899100a",
      "content": {
        "id": "29c16f99-eae1-36a9-bb00-b03a1899100a",
        "contentType": "STORY",
        "title": "Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent",
        "description": "",
        "summary": "Investing.com -- Merck (NYSE: MRK) stock rose 2% Friday morning after Deutsche Bank analyst James Shin upgraded the pharmaceutical giant from Hold to Buy, setting a price target of $150.00, up from $115.00.",
        "pubDate": "2026-02-13T13:00:36Z",
        "displayTime": "2026-02-13T13:00:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-stock-upside-why-deutsche-130036976.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-stock-upside-why-deutsche-130036976.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:57:32+00:00",
    "headline": "Where is AbbVie Inc. (ABBV) Headed According to the Street?",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best medical research stocks to buy according to hedge funds. AbbVie Inc. (NYSE:ABBV) received rating updates from Guggenheim and UBS on February 5, with Guggenheim reaffirming a Buy rating on the stock with a $242 price target and UBS revising the price target to $230 from $240 while […]",
    "url": "https://finance.yahoo.com/news/where-abbvie-inc-abbv-headed-145732866.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "cb7f05f9-de6f-36fc-98d4-401d061fc958",
      "content": {
        "id": "cb7f05f9-de6f-36fc-98d4-401d061fc958",
        "contentType": "STORY",
        "title": "Where is AbbVie Inc. (ABBV) Headed According to the Street?",
        "description": "",
        "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best medical research stocks to buy according to hedge funds. AbbVie Inc. (NYSE:ABBV) received rating updates from Guggenheim and UBS on February 5, with Guggenheim reaffirming a Buy rating on the stock with a $242 price target and UBS revising the price target to $230 from $240 while […]",
        "pubDate": "2026-02-13T14:57:32Z",
        "displayTime": "2026-02-13T14:57:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Citi Sees a More Supportive Backdrop Forming for AbbVie (ABBV) and Biopharma",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aXAa28AvezyRv056g_RUEg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lzVMSqWRbEKelBHS4c050A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/where-abbvie-inc-abbv-headed-145732866.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/where-abbvie-inc-abbv-headed-145732866.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]